|
作者：于一江 單位：淮安市中醫(yī)院內(nèi)分泌科 來源：醫(yī)學(xué)界內(nèi)分泌頻道 01 02 03 04 05 06
參考文獻(xiàn)： [1]何秉賢.二甲雙胍在高血壓防治中應(yīng)用的現(xiàn)代觀點(diǎn)[J].中華高血壓雜志,2018,26(06):508-509. [2]Racine Jenna L,Adams Jacquelyn H,Antony Kathleen M,el.Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.[J].American journal of perinatology,2021,38(11). [3]Ouyang Hong,AlMureish Abdulrahman,Wu Na.Research progress of metformin in gestational diabetes mellitus:a narrative review.[J].Annals of palliative medicine,2021,10(3). [4]楊周生,陳曉宇.二甲雙胍多效能藥理作用的研究進(jìn)展[J].中國(guó)臨床新醫(yī)學(xué),2021,14(04):422-426. [5]許桂炎,應(yīng)曉蕾,曹海輝.二甲雙胍治療高血壓并發(fā)代謝綜合征的臨床效果[J].全科醫(yī)學(xué)臨床與教育,2017,15(01):89-91. [6]蘇馨,胡蓉.高血壓合并糖尿病血壓控制的探討[J].重慶醫(yī)學(xué),2018,47(16):2219-2222. [7]劉思緒,于勝欽,張曙影.阿卡波糖心血管獲益機(jī)制及安全性的研究進(jìn)展[J].實(shí)用心腦肺血管病雜志,2019,27(11):102-106. [8]周鶴銘,周雁蘋.吡格列酮輔助治療老年2型糖尿病并高血壓的可行性[J].慢性病學(xué)雜志,2019,20(09):1384-1385+1388. [9]臧永軍,龍朦朦,劉東,等.吡格列酮治療2型糖尿病的研究進(jìn)展[J].中國(guó)醫(yī)藥指南,2017,15(36):4-5. [10]張秀龍,占長(zhǎng)河.吡格列酮聯(lián)合阿卡波糖治療老年2型糖尿病并高血壓的臨床療效[J].臨床合理用藥雜志,2019,12(09):11-12+14. [11]Kvandova M,Barancik M,Balis P,Puzserova A,Majzunova M,Dovinova I.The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability,renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats.[J].Journal of physiology and pharmacology:an official journal of the Polish Physiological Society,2018,69(2). [12]郭彩紅,高秀瑩.達(dá)格列凈對(duì)2型糖尿病伴代謝綜合征患者代謝指標(biāo)影響[J].臨床軍醫(yī)雜志,2018,46(05):585-587. [13]郝雁紅,吳清,李云,等.達(dá)格列凈在2型糖尿病合并高血壓患者中的臨床應(yīng)用[J].中國(guó)當(dāng)代醫(yī)藥,2021,28(18):12-16. [14]王菲,盧新政.卡格列凈對(duì)2型糖尿病患者心血管保護(hù)作用的研究進(jìn)展[J].心血管病學(xué)進(jìn)展,2020,41(03):231-234. [15]陳添玉,陳琪瑩,張?jiān)抡?卡格列凈對(duì)2型糖尿病患者心血管因素影響的Meta分析[J].藥物流行病學(xué)雜志,2021,30(04):239-244+288. [16]Kario Kazuomi,Okada Kenta,Kato Mitsutoshi,Nishizawa Masafumi,Yoshida Tetsuro,Asano Tsuguyoshi,Uchiyama Kazuaki,Niijima Yawara,Katsuya Tomohiro,Urata Hidenori,Osuga Jun-Ichi,Fujiwara Takeshi,Yamazaki Shoji,Tomitani Naoko,Kanegae Hiroshi.24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension:Results from the Randomized,Placebo-Controlled SACRA Study.[J].Circulation,2018,139(18). [17]周佩,唐湘宇,鄧云霞,等.SGLT-2抑制劑——恩格列凈的心血管保護(hù)作用及機(jī)制研究進(jìn)展[J].中國(guó)醫(yī)藥導(dǎo)刊,2021,23(11):823-827. [18]孫永,田琳,吳讓兵,等.2型糖尿病治療新藥恩格列凈的研究現(xiàn)狀[J].中國(guó)糖尿病雜志,2018,26(06):523-528. [19]Dilip Sharma,Suril Verma,Shivani Vaidya,el.Recent updates on GLP-1 agonists:Current advancements&challenges[J].Biomedicine&Pharmacotherapy,2018,108. [20]趙延珍,杜婧.GLP-1受體激動(dòng)劑治療2型糖尿病的研究進(jìn)展[J].老年醫(yī)學(xué)研究,2021,2(03):55-60. [21]陳涯,王艷萍,張亮,等.利拉魯肽對(duì)2型糖尿病合并動(dòng)脈粥樣硬化患者血糖、血脂、血壓和頸動(dòng)脈斑塊的影響[J].海南醫(yī)學(xué)院學(xué)報(bào),2019,25(10):730-734. [22]徐慶海,馬穎,吳艷春,等.利拉魯肽對(duì)2型糖尿病合并高血壓患者血糖、血壓及血脂的影響[J].山東醫(yī)藥,2017,57(21):77-79. [23]Younes Subhi Talal,Maeda Kenji J,Sasser Jennifer,el.The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.[J].American journal of physiology.Heart and circulatory physiology,2020,318(1). [24]張學(xué)輝,李娟.利拉魯肽降壓效應(yīng)機(jī)制的研究進(jìn)展[J].臨床醫(yī)學(xué)研究與實(shí)踐,2021,6(08):196-198. [25]Zhang Jianqiang,Chen Qiuyue,Zhong Jixin,Liu Chaohong,Zheng Bing,Gong Quan.DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy:Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.[J].Frontiers in immunology,2019,10. [26]杜鎣漩,王慧.西格列汀對(duì)糖尿病合并高血壓患者血壓、動(dòng)脈僵硬度和內(nèi)皮功能的影響[J].廣西醫(yī)學(xué),2020,42(10):1193-1197. [27]陳昇.西格列汀輔助治療糖尿病并高血壓對(duì)患者糖脂代謝、血管內(nèi)皮功能的影響[J].糖尿病新世界,2020,23(24):91-93+102. |
|
|
